PD-L1 Testing Market - Strategic Insights and Forecasts (2026-2035)

The PD-L1 Testing Market is expected to grow at a CAGR of 7.5% from a market value of USD 1.27 billion in 2026 to USD 2.45 billion in 2035.

PD-L1 testing functions as a predictive biomarker that guides immunotherapy selection across multiple solid tumors. The test measures PD-L1 protein expression on tumor cells and immune cells using validated immunohistochemistry (IHC) assays, enabling clinicians to stratify patients according to expected response to immune checkpoint blockade. As immunotherapy indications continue expanding, diagnostic demand increasingly depends on biomarker-guided treatment pathways rather than conventional histopathological classification alone.

Clinical adoption is extending beyond metastatic disease because immunotherapy is moving into earlier treatment settings, including neoadjuvant and adjuvant therapy. This expansion is increasing testing volumes in pathology laboratories while creating demand for standardized scoring methodologies, automated staining platforms, and digital pathology solutions that reduce interobserver variability.

Regulatory agencies continue strengthening the role of companion diagnostics in oncology drug approvals. Many anti-PD-1 and anti-PD-L1 therapies receive approval only when used alongside validated diagnostic assays, creating a structural dependency between pharmaceutical development and diagnostic commercialization. This co-development model encourages long-term partnerships between pharmaceutical companies and diagnostic manufacturers while accelerating synchronized regulatory submissions.

The market also reflects broader transformation within precision oncology. Comprehensive genomic profiling, multiplex immunofluorescence, spatial biology, transcriptomic analysis, and artificial intelligence-assisted pathology are complementing conventional PD-L1 testing rather than replacing it. Consequently, laboratories are adopting integrated biomarker workflows that support more personalized therapeutic decisions across increasingly heterogeneous cancer populations.

Market Dynamics

Market Drivers

• Expanding Immunotherapy Indications Increase Companion Diagnostic Demand: PD-L1 testing remains closely linked to the expanding clinical use of immune checkpoint inhibitors across oncology. Pharmaceutical sponsors are obtaining approvals for additional tumor types and earlier treatment settings, increasing the number of patients requiring biomarker evaluation before therapy initiation. This expansion creates sustained demand for validated companion diagnostic assays that demonstrate analytical reproducibility and regulatory compliance.

• Companion Diagnostic Co-Development Strengthens Commercial Adoption: Companion diagnostics represent an essential component of oncology drug development because regulatory authorities frequently require validated biomarkers during therapeutic approval. Pharmaceutical developers are integrating diagnostic partners into clinical development programs earlier to streamline regulatory submissions and accelerate commercial launches.

• Digital Pathology Is Improving Diagnostic Standardization: Interpretation variability remains a significant challenge for PD-L1 immunohistochemistry because different scoring algorithms and observer experience may influence clinical decisions. Healthcare systems increasingly recognize the importance of standardized interpretation to ensure consistent patient eligibility across institutions. Diagnostic companies are integrating artificial intelligence-assisted image analysis with digital pathology platforms to improve scoring reproducibility and laboratory efficiency.

• Multiplex Biomarker Assessment Is Reshaping Precision Oncology: Cancer biology increasingly reflects complex interactions between tumor genomics and the immune microenvironment. Single biomarker evaluation provides only partial insight into therapeutic response, encouraging broader adoption of multiplex diagnostic approaches.

Market Restraints

• Variability among PD-L1 assays, antibody clones, scoring algorithms, and companion diagnostic requirements continues to limit result harmonization across laboratories.

• Tissue availability remains constrained in several advanced cancers, reducing testing opportunities and increasing the need for repeat biopsy procedures.

• High implementation costs for digital pathology infrastructure, automated staining systems, and quality assurance programs continue restricting adoption in resource-limited healthcare settings.

Market Opportunities

• Earlier Cancer Treatment Is Expanding Testing Volumes: Immunotherapy increasingly enters neoadjuvant and adjuvant treatment settings because clinical studies demonstrate improved long-term outcomes in selected patient populations. Earlier intervention requires biomarker assessment before initial treatment planning, increasing diagnostic demand across hospitals and pathology laboratories.

• Liquid Biopsy Research Broadens Biomarker Assessment: Conventional tissue biopsy remains the clinical standard for PD-L1 evaluation, yet repeated tissue sampling presents procedural limitations for many patients. Investigators are exploring circulating tumor DNA, circulating tumor cells, and extracellular vesicles as complementary biomarker sources that enable longitudinal disease monitoring.

• Artificial Intelligence Supports Laboratory Modernization: Growing pathology workloads require scalable diagnostic workflows that improve efficiency without compromising analytical quality. Artificial intelligence is supporting automated tissue recognition, standardized PD-L1 scoring, quality control, and clinical reporting within digital pathology environments.

• Combination Immunotherapy Development Expands Biomarker Complexity: Cancer treatment increasingly utilizes combination strategies involving checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, targeted therapies, chemotherapy, and personalized vaccines. These combinations require more sophisticated patient stratification than traditional single-agent immunotherapy.

Disease & Epidemiology Analysis

Cancer remains one of the leading causes of mortality worldwide, and the increasing incidence of solid tumors continues driving demand for predictive biomarker testing. Lung cancer represents the largest clinical application for PD-L1 testing because immune checkpoint inhibitors constitute a major treatment option for both metastatic and earlier-stage non-small cell lung cancer. Expanding therapeutic indications continue to increase the number of patients requiring biomarker evaluation before treatment initiation.

Melanoma also maintains substantial dependence on PD-L1 assessment despite broader biomarker strategies because immune checkpoint blockade remains a foundational therapeutic approach. Breast cancer, particularly triple-negative breast cancer, increasingly incorporates PD-L1 testing into treatment selection as immunotherapy indications continue expanding. Gastric and gastroesophageal junction cancers, cervical cancer, urothelial carcinoma, head and neck squamous cell carcinoma, and several additional malignancies are similarly strengthening clinical demand through regulatory approvals linked to companion diagnostics.

Treatment Guidelines Landscape

Market Segmentation

By Product

Assay kits and reagents represent the largest demand center within the PD-L1 testing market because every patient evaluation requires standardized consumables regardless of laboratory size or testing frequency. Clinical adoption is increasing as immune checkpoint inhibitors receive approvals across additional tumor types, causing pathology laboratories to process higher testing volumes. Analytical consistency remains essential because treatment eligibility frequently depends on predefined PD-L1 expression thresholds established during therapeutic clinical trials. Manufacturers are therefore expanding validated companion diagnostic reagent portfolios while improving lot-to-lot reproducibility and workflow compatibility with automated staining instruments.

By Technology

Immunohistochemistry remains the clinical standard for PD-L1 assessment because virtually all approved companion diagnostics rely on validated IHC assays linked to regulatory-approved immunotherapies. Demand is expanding as hospitals continue integrating biomarker-guided treatment pathways into routine oncology practice, increasing the need for standardized tissue-based testing. Interpretation variability remains a structural challenge because different antibody clones, scoring algorithms, and therapeutic indications require disease-specific expertise.

By End User

Diagnostic laboratories account for a substantial proportion of PD-L1 testing because centralized pathology services provide standardized interpretation, quality assurance, and high-throughput testing capabilities for hospitals and oncology networks. Testing demand is increasing as healthcare systems consolidate specialized biomarker services within accredited laboratories that possess advanced automation and experienced molecular pathology personnel. Operational complexity continues rising because laboratories increasingly manage multiple companion diagnostic assays across diverse cancer indications and pharmaceutical partnerships. Service providers are investing in digital pathology, laboratory information systems, and artificial intelligence-assisted workflow optimization to improve turnaround times while maintaining analytical consistency. This operational model strengthens diagnostic quality, supports regulatory accreditation requirements, and enables efficient integration of emerging multiplex biomarker technologies.

Regional Analysis

North America Market Analysis

North America represents the most mature market for PD-L1 testing because precision oncology is firmly integrated into routine cancer management, and companion diagnostics are closely aligned with immunotherapy approvals. Clinical demand continues increasing as checkpoint inhibitors receive expanded indications across lung cancer, melanoma, triple-negative breast cancer, urothelial carcinoma, gastric cancer, cervical cancer, and several additional malignancies. This expansion requires pathology laboratories to perform standardized biomarker testing before treatment selection, increasing the utilization of validated companion diagnostic assays. Regulatory oversight remains a defining characteristic of the regional market because the U.S. Food and Drug Administration maintains rigorous requirements for analytical validation and companion diagnostic approval. Pharmaceutical sponsors increasingly coordinate diagnostic development alongside therapeutic clinical programs, reducing regulatory uncertainty while accelerating commercialization. Diagnostic manufacturers prioritize North America for new assay launches and digital pathology innovations.

Europe Market Analysis

Europe maintains a strong position in the PD-L1 testing market because precision medicine policies increasingly support biomarker-guided oncology treatment across national healthcare systems. Demand continues to expand as reimbursement authorities recognize the clinical value of companion diagnostics in optimizing immunotherapy utilization and reducing unnecessary treatment exposure. This shift encourages pathology laboratories to strengthen biomarker testing capabilities while adopting standardized quality assurance programs. Regulatory harmonization supports market expansion because the European Medicines Agency and the European Commission continue to reinforce coordinated approval pathways for therapeutics and companion diagnostics. Manufacturers increasingly conduct multinational clinical studies to generate evidence acceptable across multiple European healthcare systems. These coordinated regulatory frameworks improve commercial predictability while encouraging broader investment in diagnostic innovation.

Asia Pacific Market Analysis

Asia Pacific is experiencing the fastest structural expansion in PD-L1 testing because cancer incidence continues increasing while healthcare systems invest heavily in precision oncology infrastructure. Demand is rising as governments expand national cancer control programs, improve pathology capacity, and encourage adoption of biomarker-guided treatment pathways. The growing availability of immune checkpoint inhibitors further strengthens testing requirements across tertiary hospitals and specialized oncology centers.

Healthcare disparities continue influencing market development because advanced molecular pathology capabilities remain concentrated within major metropolitan institutions. Governments are therefore investing in laboratory modernization, workforce development, and digital health initiatives that improve diagnostic accessibility across broader patient populations. These investments gradually reduce infrastructure limitations while supporting long-term market expansion.

Rest of the World

The Rest of the World market demonstrates uneven but steadily improving adoption because oncology infrastructure varies considerably across Latin America, the Middle East, and Africa. Demand is increasing primarily within large urban cancer centers where immunotherapy availability is expanding, and precision medicine programs receive greater institutional support. Testing utilization remains concentrated in referral hospitals that possess specialized pathology expertise and access to validated companion diagnostic platforms. Resource constraints continue to limit broader implementation because advanced immunohistochemistry instrumentation, digital pathology systems, and specialized pathology personnel remain unevenly distributed.

Regulatory Landscape

The regulatory environment for PD-L1 testing increasingly reflects the convergence of therapeutic development and precision diagnostics. Companion diagnostics are no longer evaluated as independent laboratory products because regulatory agencies require evidence demonstrating that biomarker results reliably identify patients who are likely to benefit from specific immune checkpoint inhibitors. This approach strengthens analytical validation requirements while encouraging pharmaceutical sponsors to integrate diagnostic strategy early in clinical development. Regulatory authorities continue emphasizing clinical concordance, reproducibility, and quality management throughout assay development and commercialization.

The U.S. Food and Drug Administration maintains one of the most mature companion diagnostic frameworks, requiring synchronized review of therapeutics and associated diagnostic assays for many immuno-oncology products. Similar regulatory principles are increasingly reflected by the European Medicines Agency, while implementation of the European Union In Vitro Diagnostic Regulation is strengthening evidence requirements for in vitro diagnostic devices marketed across Europe. Manufacturers are consequently investing earlier in analytical validation, multicenter clinical studies, and post-market performance monitoring to satisfy evolving regulatory expectations.

Pipeline Analysis

The PD-L1 testing pipeline increasingly evolves in parallel with the development of next-generation immunotherapies rather than through standalone diagnostic innovation. Pharmaceutical sponsors continue expanding clinical programs involving PD-1 inhibitors, PD-L1 inhibitors, bispecific antibodies, antibody-drug conjugates, personalized cancer vaccines, tumor-infiltrating lymphocyte therapies, and cell-based immunotherapies. These investigational treatments require increasingly sophisticated biomarker strategies because PD-L1 expression alone does not consistently predict therapeutic response across all tumor types. Diagnostic developers are therefore integrating PD-L1 with complementary biomarkers, including tumor mutational burden (TMB), microsatellite instability (MSI), gene expression signatures, and spatial immune profiling.

Clinical progression continues emphasizing earlier treatment settings because numerous Phase II and Phase III studies investigate checkpoint inhibitors in neoadjuvant and adjuvant disease. These programs increase biomarker testing before definitive surgery rather than only in metastatic disease, expanding diagnostic utilization throughout the patient journey. Diagnostic manufacturers are aligning assay development with these evolving therapeutic strategies, positioning integrated biomarker solutions as an essential component of future precision oncology workflows.

Reimbursement Landscape

Reimbursement policies increasingly recognize PD-L1 testing as a prerequisite for evidence-based immunotherapy selection rather than an optional laboratory procedure. Coverage decisions in several developed healthcare systems support companion diagnostics when they are explicitly referenced within approved therapeutic labeling or national clinical practice guidelines. This linkage encourages routine biomarker testing while improving access to targeted immunotherapies for eligible patients.

Healthcare payers continue evaluating diagnostic value based on clinical utility, analytical validity, and the ability to avoid ineffective treatment. Hospitals and pathology laboratories are therefore emphasizing standardized testing protocols, laboratory accreditation, and validated companion diagnostic platforms that satisfy payer expectations. As precision oncology expands into earlier disease stages and combination treatment strategies, reimbursement frameworks are expected to evolve toward supporting broader multiplex biomarker assessment alongside conventional PD-L1 testing.

Competitive Landscape

F. Hoffmann-La Roche Ltd.

Roche remains a global leader in companion diagnostics through its Ventana pathology portfolio and long-standing collaborations with immuno-oncology drug developers. The company continues strengthening automated tissue diagnostics and digital pathology capabilities to support precision oncology and biomarker-driven treatment decisions.

Agilent Technologies

Agilent expands its PD-L1 testing portfolio through Dako companion diagnostic assays that support multiple approved immunotherapies. The company focuses on assay standardization, laboratory automation, and integrated pathology solutions to improve diagnostic consistency.

Abbott Laboratories

Abbott leverages its global diagnostics infrastructure to support precision oncology through molecular and immunodiagnostic technologies. The company continues investing in advanced diagnostic platforms that complement evolving biomarker-guided cancer care.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific provides comprehensive pathology instruments, antibodies, reagents, and molecular diagnostic solutions supporting oncology research and clinical laboratories. Its strategy emphasizes integrated laboratory workflows and next-generation precision medicine technologies.

QIAGEN N.V.

QIAGEN strengthens precision oncology through molecular diagnostic assays, bioinformatics solutions, and companion diagnostic collaborations with pharmaceutical companies. The company continues expanding biomarker testing capabilities across tissue- and nucleic acid-based platforms.

Bio-Rad Laboratories, Inc.

Bio-Rad supports oncology diagnostics through high-quality antibodies, reagents, digital PCR systems, and laboratory quality control products. Its portfolio addresses the growing demand for standardized biomarker analysis and research applications.

Bio-Techne Corporation

Bio-Techne focuses on advanced antibodies, multiplex immunoassays, spatial biology, and cell analysis technologies that enhance cancer biomarker discovery. The company is expanding precision medicine capabilities through innovative research and translational diagnostic tools.

Merck KGaA

Merck KGaA supports precision oncology through life science research reagents, antibodies, and laboratory technologies used in biomarker development. The company continues investing in translational research platforms that enable next-generation immuno-oncology diagnostics.

Key Developments

• July 2026: Abbisko Therapeutics and AstraZeneca entered into a strategic collaboration to jointly conduct a multicenter Phase I/II clinical trial combining lumipodlin (ABSK043), a first-in-class oral PD-L1 inhibitor, with AstraZeneca's EGFR-TKI Tagrisso (osimertinib) for patients with EGFR-mutated and PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The trial specifically targets patients with PD-L1-positive NSCLC, as PD-L1 testing is required to determine eligibility for this combination therapy.

• June 2026: Agilent Technologies received FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006. It is for use on the Dako Omnis platform to identify patients with esophageal squamous cell carcinoma (ESCC), triple-negative breast cancer (TNBC), cervical cancer, and gastric or gastroesophageal junction (GEJ) adenocarcinoma who may be eligible for treatment with KEYTRUDA (pembrolizumab).

Strategic Insights and Future Market Outlook

The PD-L1 testing market is transitioning from single-marker companion diagnostics toward integrated immune profiling because oncology treatment increasingly depends on multiple predictive biomarkers rather than isolated protein expression. Pharmaceutical sponsors are designing clinical trials that combine checkpoint inhibitors with targeted therapies, antibody-drug conjugates, bispecific antibodies, and cell-based therapies, increasing demand for multiplex diagnostic platforms capable of evaluating complex tumor biology. This evolution strengthens the role of digital pathology, artificial intelligence-assisted image analysis, and spatial biology technologies within routine clinical practice.

Regulatory agencies continue reinforcing companion diagnostic requirements while precision oncology expands into earlier treatment settings. Diagnostic manufacturers are therefore aligning product development with evolving therapeutic pipelines, emphasizing automation, standardized interpretation, and integrated laboratory workflows. Companies capable of combining validated companion diagnostics with digital pathology and comprehensive biomarker analysis are likely to strengthen their competitive positions as clinical decision-making becomes increasingly data-driven.

The market also reflects growing collaboration between pharmaceutical developers, diagnostic manufacturers, academic cancer centers, and healthcare providers. These partnerships accelerate biomarker validation, improve assay harmonization, and support the clinical adoption of emerging technologies such as liquid biopsy and artificial intelligence-enabled pathology. As oncology care continues shifting toward personalized treatment strategies, PD-L1 testing is expected to remain a foundational biomarker while becoming part of broader precision oncology platforms that integrate genomic, transcriptomic, and immune profiling.

PD-L1 Testing Market Scope: